<DOC>
	<DOC>NCT00279045</DOC>
	<brief_summary>The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.</brief_summary>
	<brief_title>Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Inclusion criteria: Newly diagnosed patients (&lt; 3years) with type 2 diabetes. Fasting plasma glucose (FPG) range of 126240 mg/dL at Screening. No previous treatment with oral or parenteral glucoselowering therapy. Exclusion criteria: History of lactic acidosis. Anemia (&lt;11g for males, &lt;10 g for females). Unstable or severe NY Heart Associationclass 3 or 4. Any NY Heart Association congestive heart failure. Patients with chronic diseases requiring periodic or intermittent treatment with oral or intravenous corticosteroids.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>type 2 diabetes monotherapy treatment naive</keyword>
</DOC>